Savara News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

14.02.23	Savara Announces New Leadership Appointments (Businesswire)
20.01.23	Savara Announces New Employment Inducement Grant (Businesswire)
22.11.22	Savara Announces New Employment Inducement Grant (Businesswire)
10.11.22	Savara Reports Third Quarter 2022 Financial Results and Provides Business Update (Businesswire)
09.11.22	Savara to Participate in Three Upcoming Investor Conferences (Businesswire)
14.09.22	Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Businesswire)
06.09.22	Savara Presented Data at the European Respiratory Society (ERS) International Congress 2022 (Businesswire)
01.09.22	Savara to Present at H.C. Wainwright 24th Annual Global Investment Conference (Businesswire)
26.08.22	Savara Announces Resignation of Chief Medical Officer (Businesswire)
25.08.22	Savara Awarded Promising Innovative Medicine (PIM) Designation in the United Kingdom (UK) for Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) (Businesswire)
11.08.22	Savara Reports Second Quarter 2022 Financial Results and Provides Business Update (Businesswire)
11.07.22	Savara Announces Acceptance of Three Abstracts at the European Respiratory Society (ERS) International Congress 2022 (Businesswire)
16.06.22	Savara Awarded Innovation Passport in United Kingdom (UK) for Molgramostim Nebulizer Solution (Molgramostim), a Novel Investigational Inhaled Biologic (Businesswire)
01.06.22	Savara to Present at Jefferies Healthcare Conference (Businesswire)
17.05.22	Savara to Present at H.C. Wainwright Global Investment Conference (Businesswire)
11.05.22	Savara Reports First Quarter 2022 Financial Results and Provides Business Update (Businesswire)
26.04.22	Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Businesswire)
22.04.22	Savara Announces Debt Refinancing of $26.5M Credit Facility With Silicon Valley Bank (Businesswire)
30.03.22	Savara Reports Fourth Quarter / Year-End 2021 Financial Results and Provides Business Update (Businesswire)
16.03.22	Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Businesswire)
09.03.22	Savara to Present at Oppenheimer’s 32nd Annual Healthcare Conference (Businesswire)
30.06.21	Savara Announces First Patient Dosed in Pivotal Phase 3 Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Trial (Businesswire)
26.05.21	Savara to Present at the Jefferies Virtual Healthcare Conference (Businesswire)
17.05.21	Savara to Present at the Oppenheimer Rare & Orphan Disease Virtual Summit (Businesswire)
14.05.21	Savara Announces New Employment Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Businesswire)
13.05.21	Savara Reports First Quarter 2021 Financial Results and Provides Business Update (Businesswire)
31.03.21	März 2021: So schätzen Experten die Savara-Aktie ein (finanzen.net)
15.03.21	Savara Announces Closing of $130 Million Public Offering Following Full Exercise of Underwriters’ Option (Businesswire)
11.03.21	Savara Announces Pricing of Public Offering of Common Stock (Businesswire)
10.03.21	Savara Announces Proposed Public Offering of Common Stock (Businesswire)
24.02.21	BLUE To Face FDA Next Month, SNSS Catches Eyes, ADVM On Watch (RTTNews)
10.12.20	Savara Provides Pipeline and Business Update (Businesswire)
24.11.20	Savara Announces Participation in Fireside Chats at Two Upcoming Virtual Investor Healthcare Conferences (Businesswire)
11.11.20	Savara to Present at the Jefferies Virtual London Healthcare Conference (Businesswire)
05.11.20	Savara Reports Third Quarter 2020 Financial Results and Provides Business Update (Businesswire)
11.09.20	Savara Announces Senior Management Changes (Businesswire)
09.09.20	Savara to Present at the 22nd Annual H.C. Wainwright Annual Investment Conference Being Held Virtually (Businesswire)
08.09.20	Savara Announces New England Journal of Medicine (NEJM) Publication of IMPALA Study Results (Businesswire)
03.09.20	Savara to Discontinue Exploratory ENCORE Study Evaluating Molgradex for the Treatment of NTM Lung Infection in People Living With Cystic Fibrosis (CF) (Businesswire)
06.08.20	Savara Reports Second Quarter 2020 Financial Results and Provides Business Update (Businesswire)
05.08.20	Savara to Present at the 40th Annual Canaccord Genuity Global Growth Conference to be Held Virtually (Businesswire)
30.07.20	Savara to Report Second Quarter 2020 Financial Results and Provide Business Update (Businesswire)
27.05.20	Savara to Present at the Jefferies Virtual Healthcare Conference (Businesswire)
08.05.20	Savara Announces Change of Date for 2020 Annual Meeting of Stockholders (Businesswire)
07.05.20	Savara Reports First Quarter 2020 Financial Results and Provides Business Update (Businesswire)
30.04.20	Savara to Report First Quarter 2020 Financial Results and Provide Business Update (Businesswire)
02.04.20	Savara Obtains Global Rights to Develop and Commercialize Apulmiq (Businesswire)
31.03.20	AMRN Loses Legal Fight, AKRO Awaits Big Day, JNJ's Covid-19 Vaccine Study In Sep (RTTNews)
30.03.20	Savara Provides Business Update in Response to COVID-19 Pandemic (Businesswire)
12.03.20	Savara Reports Fourth Quarter / Year-End 2019 Financial Results and Provides Business Update (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	79.88	2.70 %	K V
Roche Hldg G	264.40	2.68 %	K V
Lonza Grp	554.20	2.29 %	K V
Swiss Re	134.85	1.70 %	K V
Novartis	90.39	1.61 %	K V
ABB	49.48	-0.26 %	K V
Geberit	513.60	-0.35 %	K V
Sika	216.90	-0.37 %	K V
Kuehne+Nagel Int	208.50	-0.43 %	K V
Holcim	88.08	-0.45 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Savara Inc Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten